Hector de Leon, MD
Child & Adolescent Psychiatry · Tavares, FLNPI 1821023268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $877, 2.1 times the $408 reported in 2019.
Across 250 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$556
- Otsuka America Pharmaceutical, Inc.$514
- Takeda Pharmaceuticals U.S.A., Inc.$428
- Neurocrine Biosciences, Inc.$404
- AbbVie$378
- Tris Pharma Inc$314
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,806100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 27 | $556 |
| Otsuka America Pharmaceutical, Inc. | 29 | $514 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $428 |
| Neurocrine Biosciences, Inc. | 15 | $404 |
| AbbVie(2 entities) | 19 | $378 |
| Tris Pharma Inc | 18 | $314 |
| Corium, LLC | 17 | $301 |
| Lundbeck LLC | 14 | $262 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $215 |
| Sunovion Pharmaceuticals Inc. | 9 | $169 |
| Vanda Pharmaceuticals Inc. | 6 | $136 |
| Axsome Therapeutics, Inc. | 6 | $125 |
| Ironshore Pharmaceuticals Inc. | 5 | $94 |
| Jazz Pharmaceuticals Inc. | 5 | $87 |
| Merck | 5 | $84 |
| Almatica Pharma LLC | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 4 | $74 |
| Idorsia Pharmaceuticals US Inc | 5 | $73 |
| Alkermes, Inc. | 3 | $68 |
| Collegium Pharmaceutical, Inc. | 3 | $63 |
| Neuronetics, Inc. | 4 | $58 |
| Validus Pharmaceuticals LLC | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Shire North American Group Inc | 2 | $39 |
| Noven Therapeutics, LLC | 2 | $33 |
| Neos Therapeutics, LP | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
How this compares
$4,806 in reported general payments places this provider in the 85th percentile of 206 child & adolescent psychiatry providers in Florida.
See all child & adolescent psychiatry providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 41 | $68,585 |
| Lurasidone Hcl | 43 | $18,025 |
| Aripiprazole | 288 | $12,360 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $9,909 |
| Effexor XrVenlafaxine Hcl | 12 | $6,976 |
| BelsomraSuvorexant | 12 | $5,280 |
| Lisdexamfetamine Dimesylate | 20 | $4,830 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 158 | $4,284 |
| Quetiapine Fumarate | 152 | $3,819 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 124 | $3,664 |
| Trazodone Hcl | 229 | $2,212 |
| Duloxetine Hcl | 121 | $1,998 |
| Vilazodone Hcl | 19 | $1,946 |
| Alprazolam | 299 | $1,907 |
| Lamotrigine | 149 | $1,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $514 | $68,58541 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $428 | $9,90922 claims |
| MerckBelsomra | $84 | $5,28012 claims |
| Almatica Pharma LLCSertraline Hcl | $83 | $69780 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 206 child & adolescent psychiatry providers in Florida.
Other child & adolescent psychiatry in Tavares
- Craig KuninsGulfport$265K
- Elias SarkisGainesville$169K
- Jeffrey AlvaroSt Petersburg$87K
- Rosa Negron MunozLakeland$39K
- Sean HoranMiami$17K
- Rachel AgustinesLargo$16K
- Carlos BorgeSarasota$15K
- Justin SpoonerPonte Vedra Beach$12K
- Bhaskar RajuOrlando$11K
- Americo PadillaMiami$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.